Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections contributes to a substantial proportion of liver disease worldwide. The aim of this study was to assess the clinical and virological features of HBV-HCV co-infection.Demographic data were collected for 3238 high-risk people from an HC...

Full description

Bibliographic Details
Main Authors: Ge Yu, Xiumei Chi, Ruihong Wu, Xiaomei Wang, Xiuzhu Gao, Fei Kong, Xiangwei Feng, Yuanda Gao, Xinxing Huang, Jinglan Jin, Yue Qi, Zhengkun Tu, Bing Sun, Jin Zhong, Yu Pan, Junqi Niu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4589515?pdf=render
id doaj-21baed23cdeb4151af3ede95a952f3cf
record_format Article
spelling doaj-21baed23cdeb4151af3ede95a952f3cf2020-11-25T00:28:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013901510.1371/journal.pone.0139015Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.Ge YuXiumei ChiRuihong WuXiaomei WangXiuzhu GaoFei KongXiangwei FengYuanda GaoXinxing HuangJinglan JinYue QiZhengkun TuBing SunJin ZhongYu PanJunqi NiuHepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections contributes to a substantial proportion of liver disease worldwide. The aim of this study was to assess the clinical and virological features of HBV-HCV co-infection.Demographic data were collected for 3238 high-risk people from an HCV-endemic region in China. Laboratory tests included HCV antibody and HBV serological markers, liver function tests, and routine blood analysis. Anti-HCV positive samples were analyzed for HCV RNA levels and subgenotypes. HBsAg-positive samples were tested for HBV DNA.A total of 1468 patients had chronic HCV and/or HBV infections. Among them, 1200 individuals were classified as HCV mono-infected, 161 were classified as HBV mono-infected, and 107 were classified as co-infected. The HBV-HCV co-infected patients not only had a lower HBV DNA positive rate compared to HBV mono-infected patients (84.1% versus 94.4%, respectively; P < 0.001). The median HCV RNA levels in HBV-HCV co-infected patients were significantly lower than those in the HCV mono-infected patients (1.18[Interquartile range (IQR) 0-5.57] versus 5.87[IQR, 3.54-6.71] Log10 IU/mL, respectively; P < 0.001). Furthermore, co-infected patients were less likely to have detectable HCV RNA levels than HCV mono-infected patients (23.4% versus 56.5%, respectively; P < 0.001). Those HBV-HCV co-infected patients had significantly lower median HBV DNA levels than those mono-infected with HBV (1.97[IQR, 1.3-3.43] versus 3.06[IQR, 2-4.28] Log10 IU/mL, respectively; P < 0.001). The HBV-HCV co-infection group had higher ALT, AST, ALP, GGT, APRI and FIB-4 levels, but lower ALB and total platelet compared to the HBV mono-infection group, and similar to that of the HCV mono-infected group.These results suggest that co-infection with HCV and HBV inhibits the replication of both viruses. The serologic results of HBV-HCV co-infection in patients suggests more liver injury compared to HBV mono-infected patients, but is similar to HCV mono-infection.http://europepmc.org/articles/PMC4589515?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Ge Yu
Xiumei Chi
Ruihong Wu
Xiaomei Wang
Xiuzhu Gao
Fei Kong
Xiangwei Feng
Yuanda Gao
Xinxing Huang
Jinglan Jin
Yue Qi
Zhengkun Tu
Bing Sun
Jin Zhong
Yu Pan
Junqi Niu
spellingShingle Ge Yu
Xiumei Chi
Ruihong Wu
Xiaomei Wang
Xiuzhu Gao
Fei Kong
Xiangwei Feng
Yuanda Gao
Xinxing Huang
Jinglan Jin
Yue Qi
Zhengkun Tu
Bing Sun
Jin Zhong
Yu Pan
Junqi Niu
Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
PLoS ONE
author_facet Ge Yu
Xiumei Chi
Ruihong Wu
Xiaomei Wang
Xiuzhu Gao
Fei Kong
Xiangwei Feng
Yuanda Gao
Xinxing Huang
Jinglan Jin
Yue Qi
Zhengkun Tu
Bing Sun
Jin Zhong
Yu Pan
Junqi Niu
author_sort Ge Yu
title Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
title_short Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
title_full Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
title_fullStr Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
title_full_unstemmed Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population.
title_sort replication inhibition of hepatitis b virus and hepatitis c virus in co-infected patients in chinese population.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infections contributes to a substantial proportion of liver disease worldwide. The aim of this study was to assess the clinical and virological features of HBV-HCV co-infection.Demographic data were collected for 3238 high-risk people from an HCV-endemic region in China. Laboratory tests included HCV antibody and HBV serological markers, liver function tests, and routine blood analysis. Anti-HCV positive samples were analyzed for HCV RNA levels and subgenotypes. HBsAg-positive samples were tested for HBV DNA.A total of 1468 patients had chronic HCV and/or HBV infections. Among them, 1200 individuals were classified as HCV mono-infected, 161 were classified as HBV mono-infected, and 107 were classified as co-infected. The HBV-HCV co-infected patients not only had a lower HBV DNA positive rate compared to HBV mono-infected patients (84.1% versus 94.4%, respectively; P < 0.001). The median HCV RNA levels in HBV-HCV co-infected patients were significantly lower than those in the HCV mono-infected patients (1.18[Interquartile range (IQR) 0-5.57] versus 5.87[IQR, 3.54-6.71] Log10 IU/mL, respectively; P < 0.001). Furthermore, co-infected patients were less likely to have detectable HCV RNA levels than HCV mono-infected patients (23.4% versus 56.5%, respectively; P < 0.001). Those HBV-HCV co-infected patients had significantly lower median HBV DNA levels than those mono-infected with HBV (1.97[IQR, 1.3-3.43] versus 3.06[IQR, 2-4.28] Log10 IU/mL, respectively; P < 0.001). The HBV-HCV co-infection group had higher ALT, AST, ALP, GGT, APRI and FIB-4 levels, but lower ALB and total platelet compared to the HBV mono-infection group, and similar to that of the HCV mono-infected group.These results suggest that co-infection with HCV and HBV inhibits the replication of both viruses. The serologic results of HBV-HCV co-infection in patients suggests more liver injury compared to HBV mono-infected patients, but is similar to HCV mono-infection.
url http://europepmc.org/articles/PMC4589515?pdf=render
work_keys_str_mv AT geyu replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT xiumeichi replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT ruihongwu replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT xiaomeiwang replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT xiuzhugao replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT feikong replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT xiangweifeng replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT yuandagao replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT xinxinghuang replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT jinglanjin replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT yueqi replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT zhengkuntu replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT bingsun replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT jinzhong replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT yupan replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
AT junqiniu replicationinhibitionofhepatitisbvirusandhepatitiscvirusincoinfectedpatientsinchinesepopulation
_version_ 1725335213644447744